

COPY OF PAPER IS
ORIGINALLY FILED

1007 Rec'd PCT/PTO 11 FEB 2002 PCT


PATENT

Attorney Reference Number 899-59399

RECEIVED

APR 03 2002

TECH CENTER 1600/2900



1/15/02 899-59399 92713

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of: Johnson *et al*

Art Unit: 1645

Application No. 09/890,806

CERTIFICATE OF MAILING

Filed: November 16, 2001

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on January 15, 2002, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

For: INHIBITION OF THE MHC CLASS II
ANTIGEN PRESENTATION PATHWAY
AND PRESENTATION TO CD4+ CELLS

Examiner:

Date: January 15, 2002

Tanya M. Harding, Ph.D.
Attorney for Applicant

TRANSMITTAL LETTER

Office of Initial Patent Examination
Customer Service Center
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

- ☒ Request for Corrected Official Filing Receipt
- ☒ Exhibit A
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP


By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing

COPY OF PAPERS
ORIGINALLY FILED

TMH:kam 01/15/02 899-59399 92506



PATENT
Attorney Reference No. 899-59399

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Johnson *et al*

Application No. 09/890,806

Filed: November 16, 2001

For: INHIBITION OF THE MHC CLASS II
ANTIGEN PRESENTATION PATHWAY
AND PRESENTATION TO CD4+ CELLS

Art Unit:

Examiner:

Date: January 15, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service on 1/15/2002 as First Class Mail in an envelope addressed to: Office of Initial Patent Examination Customer Service Center, COMMISSIONER FOR PATENTS, Washington, DC 20231.

Tanya M. Harding, Ph.D.
Attorney for Applicant(s)

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Office of Initial Patent Examination
Customer Service Center
COMMISSIONER FOR PATENTS
Washington, DC 20231

Sir:

Applicants received the official Filing Receipt for the application referenced above, a copy of which (with requested correction shown in red ink) is attached as Exhibit A.

The following error(s) appears on the Filing Receipt:

The number of independent claims is incorrectly identified as "6." Please correct the number of independent claims to read -9--.

Applicant requests that the identified error(s) be corrected and that a new official Filing Receipt be issued.

Please call the undersigned if any further information is required.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

RECEIVED

APR 03 2002

TECH CENTER 1600/2900




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/890,806	11/16/2001	1645	812	899-59399	8	38	6-9

24197
KLARQUIST SPARKMAN, LLP
121 SW SALMON STREET
SUITE 1600
PORTLAND, OR 97204



CONFIRMATION NO. 6730
REPLACEMENT FILING RECEIPT



OC000000007167049

Date Mailed: 12/07/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

David C. Johnson, Portland, OR;
Roman Tomazin, Burnaby, CANADA;
Jessica Boname, Cambridge, UNITED KINGDOM;
Nagendra R. Hegde, Portland, OR;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US00/02740 02/02/2000
WHICH CLAIMS BENEFIT OF 60/118,287 02/02/1999

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No


Early Publication Request: No

** SMALL ENTITY **

Title

Inhibition of the mhc class II antigen presentation pathway and presentation to cd4+cells

Preliminary Class



435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

COPY OF PAPERS
ORIGINALLY FILED

COPY

PATENT

Attorney Reference Number 899-59399

TMH:kam 1/15/02 899-59399 92713



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Johnson *et al*

Art Unit: 1645

Application No. 09/890,806

CERTIFICATE OF MAILING

Filed: November 16, 2001

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on January 15, 2002, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

For: INHIBITION OF THE MHC CLASS II
ANTIGEN PRESENTATION PATHWAY
AND PRESENTATION TO CD4+ CELLS

Examiner:

Date: January 15, 2002

Tanya M. Harding, Ph.D.
Attorney for Applicant

TRANSMITTAL LETTER

Office of Initial Patent Examination
Customer Service Center
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

- ☒ Request for Corrected Official Filing Receipt
- ☒ Exhibit A
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing